Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

被引：0
|
作者：
Avasarala, Jagannadha [1 ]
机构：
[1] Univ Kentucky Med Ctr, Dept Neurol, 740 S Limestone, Lexington, KY 40536 USA
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2024年 / 90卷 / 12期
关键词：
Anti-CD20; drugs; B cell repopulation; CD19 cell counts; COVID; 19; susceptibility; dosing frequency; multiple sclerosis; vaccine response; DEPLETION;
D O I：
10.1111/bcp.16248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：3094 / 3096
页数：3
相关论文
共 50 条
  • [21] Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
    van Kempen, Zoe L. E.
    Hogenboom, Laura
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (05) : 693 - 695
  • [22] Chronic active MRI lesions in multiple sclerosis patients undergoing anti-CD20 antibody therapies
    Ben Ayad, A.
    Sellimi, A.
    Wynen, M.
    Bugli, C.
    Mullins, W. A.
    Kalaitzidis, G.
    Lolli, V.
    Perrotta, G.
    El Sankari, S.
    Duprez, T.
    Beck, E. S.
    Li, X.
    van Pesch, V.
    Calabresi, P. A.
    Reich, D. S.
    Absinta, M.
    Maggi, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 476 - 477
  • [23] Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 vaccine in a cohort of patients with multiple sclerosis
    Correa-Diaz, E. P.
    Barrera Madera, R.
    Torres Herran, G.
    Jacome Sanchez, C.
    Gualotuna Pachacama, W.
    Llerena Pallango, A.
    Piedra Andrade, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 838 - 838
  • [24] Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
    Bar-Or, Amit
    O'Brien, Susan M.
    Sweeney, Michael L.
    Fox, Edward J.
    Cohen, Jeffrey A.
    CNS DRUGS, 2021, 35 (09) : 985 - 997
  • [25] Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
    Amit Bar-Or
    Susan M. O’Brien
    Michael L. Sweeney
    Edward J. Fox
    Jeffrey A. Cohen
    CNS Drugs, 2021, 35 : 985 - 997
  • [26] Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review
    Etemadifar, Masoud
    Nouri, Hosein
    Sedaghat, Nahad
    Ramezani, Aryana
    Kargaran, Parisa K.
    Salari, Mehri
    Kaveyee, Hasan
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2024, 91
  • [27] Nucleocapsid Antigenemia in Patients Receiving Anti-CD20 Therapy With Protracted COVID-19
    Wilber, Eli
    Piantadosi, Anne
    Babiker, Ahmed
    McLendon, Kaleb
    O'Sick, William
    Fitts, Eric
    Webster, Andrew S.
    Verkerke, Hans
    Kim, James S.
    Phadke, Varun K.
    Rouphael, Nadine
    Titanji, Boghuma K.
    Blake, William T.
    Howard-Anderson, Jessica
    Roback, John D.
    Lam, Wilbur A.
    Damhorst, Gregory L.
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (08):
  • [28] Longitudinal COVID-19 immune trajectories in autoimmune patients on anti-CD20 therapy
    Bazzi, S.
    Maguire, C.
    Holay, N.
    Geltman, J.
    Hurley, K.
    Ehrlich, L.
    Triplett, T.
    Melamed, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 230 - 230
  • [29] Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications-A pilot study
    Moser, Tobias
    Otto, Ferdinand
    O'Sullivan, Ciara
    Hitzl, Wolfgang
    Pilz, Georg
    Harrer, Andrea
    Trinka, Eugen
    Wipfler, Peter
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 59
  • [30] Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
    Jeantin, Lina
    Abdi, Basma
    Soulie, Cathia
    Sterlin, Delphine
    Maillart, Elisabeth
    Beigneux, Ysoline
    Hippolyte, Amandine
    Belin, Lisa
    Marcelin, Anne-Genevieve
    Pourcher, Valerie
    Louapre, Celine
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (01): : 19 - 28
12345